Maverick Capital Ltd. Sells 15,968 Shares of Labcorp Holdings Inc. $LH

Posted by Brenda Bartman on Jul 30th, 2026

Maverick Capital Ltd. lowered its holdings in Labcorp Holdings Inc. (NYSE:LH – Free Report) by 90.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,596 shares of the medical research company’s stock after selling 15,968 shares during the period. Maverick Capital Ltd.’s holdings in Labcorp were worth $426,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Labcorp during the 4th quarter valued at $26,000. Hilton Head Capital Partners LLC bought a new stake in shares of Labcorp during the 4th quarter valued at $27,000. JPL Wealth Management LLC bought a new stake in shares of Labcorp during the 3rd quarter valued at $28,000. Eagle Bay Advisors LLC purchased a new stake in Labcorp during the 4th quarter worth about $29,000. Finally, DV Equities LLC purchased a new stake in Labcorp during the 4th quarter worth about $29,000. 95.94% of the stock is owned by institutional investors.

Insider Buying and Selling at Labcorp

In other news, EVP Kathryn W. Kyle sold 92 shares of the firm’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total transaction of $26,329.48. Following the sale, the executive vice president owned 3,904 shares in the company, valued at approximately $1,117,285.76. This trade represents a 2.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Bryan T. Vaughn sold 234 shares of Labcorp stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $66,968.46. Following the sale, the executive vice president directly owned 6,746 shares of the company’s stock, valued at $1,930,637.74. This represents a 3.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 6,991 shares of company stock worth $1,796,696 over the last three months. 0.84% of the stock is owned by insiders.

Labcorp Price Performance

Labcorp stock opened at $307.07 on Thursday. The stock has a market cap of $25.18 billion, a price-to-earnings ratio of 27.20, a PEG ratio of 2.09 and a beta of 0.89. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. The business has a 50-day simple moving average of $272.53 and a 200 day simple moving average of $270.29. Labcorp Holdings Inc. has a 52 week low of $244.52 and a 52 week high of $315.77.

Labcorp (NYSE:LH – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $4.09 by $0.16. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The firm had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.51 billion. During the same quarter last year, the firm posted $3.84 EPS. The company’s revenue was up 5.8% compared to the same quarter last year. On average, research analysts forecast that Labcorp Holdings Inc. will post 18 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 28th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Friday, August 28th. Labcorp’s dividend payout ratio (DPR) is currently 25.51%.

Analysts Set New Price Targets

A number of research firms have weighed in on LH. Bank of America lifted their target price on Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a report on Monday, July 13th. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Weiss Ratings raised shares of Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, July 24th. Evercore reaffirmed an “outperform” rating and set a $300.00 target price on shares of Labcorp in a report on Wednesday, April 8th. Finally, Robert W. Baird increased their target price on shares of Labcorp from $335.00 to $338.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $315.33.

Check Out Our Latest Research Report on Labcorp

Labcorp Profile

(Free Report)

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.